Author

N. Skuli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:cell signaling & trafficking· 2 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. Keith· 2 shared C. Li· 2 shared M. C. Simon· 2 shared A. A. Moverley· 1 shared A. Bakayoko· 1 shared A. D'Alessandro· 1 shared A. DeVine· 1 shared A. L. Good· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Keith

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Chemoresistance of TP53 mutant AML requires the mevalonate byproduct, GGPP, for regulation of ROS and induction of a mitochondria stress response

S. J. Skuli, A. Bakayoko, M. Kruidenier, B. Manning, P. Pammer, A. Salimov, O. Riley, G. Brake-Silla, M. Bowman, L. N. Martinez-Gutierrez, R. Buono, M. Paul, E. Saland, S. Wong, J. Xu, , M. Carroll

This study identifies GGPP, a mevalonate pathway byproduct, as critical for chemoresistance in TP53mut AML through ROS regulation and mitochondria stress response, suggesting statin-based therapies could be effective.

bioRxiv · Jun 7, 2024 · PreprintCancer Biology

Nuclear speckles regulate HIF-2α programs and correlate with patient survival in kidney cancer

K. A. Alexander, R. Yu, N. Skuli, N. J. Coffey, S. Nguyen, C. Faunce, H. Huang, I. Dardani, A. L. Good, J. Lim, C. Li, N. Biddle, E. F. Joyce, A. Raj, D. Lee, , S. L. Berger

This study shows nuclear speckles vary in cancer, correlate with survival in kidney cancer, and are regulated by HIF-2 through speckle targeting motifs.

bioRxiv · Sep 14, 2023 · PreprintCancer Biology

A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies

X. Liu, S. A. Devadiga, R. F. Stanley, R. Moroow, K. Janssen, M. Quesnel-Vallieres, O. Pomp, A. A. Moverley, C. Li, N. Skuli, M. P. Carroll, J. Huang, D. C. Wallace, K. W. Lynch, O. Abdel-Wahab, P. S. Klein

This study shows that SRSF2 mutations disrupt mitochondrial mRNA splicing, impair complex I function, and increase mitophagy through a PINK1 splicing mechanism, identifying mitophagy as a therapeutic target in MDS and AML.

bioRxiv · Jun 25, 2023 · PreprintCancer Biology

Oncogene-induced matrix reorganization controls CD8+ T cell function in the soft-tissue sarcoma microenvironment

A. M. Fuller, H. C. Pruitt, Y. Liu, V. M. Irizarry-Negron, H. Pan, H. Song, A. DeVine, R. S. Katti, S. Devalaraja, G. E. Ciotti, M. Gonzalez, E. F. Williams, I. Murazzi, D. Ntekoumes, N. Skuli, , T. S. K. Eisinger-Mathason

This study identifies YAP1-driven collagen VI deposition in sarcoma as a mechanism suppressing CD8+ T cell function through ECM remodeling and autophagy inhibition.

bioRxiv · Mar 31, 2022Cancer Biology